


IN THE SPECIFICATION:

Kindly replace the paragraph beginning on page 5, line 9 with the following:

~~IV~~ The invention is therefore first directed to a novel use of beta-naphthoquinone derivatives for making drugs with an inhibitory effect on the extracellular glutamate release, wherein said derivatives are selected among the group consisting of:


- (i) compounds having the formula (I):



(I)

wherein R represents -NH-CO-NH₂, -NH-CO-CH₃, or -OH group,

- (ii) glucuronide derivatives thereof having the formula (II):




(II)

- (iii) addition salts thereof.

Kindly replace the paragraph beginning on Page 7, line 28 and ending on Page 8, line 24, with the following:


Thus the present invention further relates to a method for treating and/or preventing glutamate-evoked cytotoxicity in a patient in need thereof comprising administering to said patient a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said derivative is selected among the group consisting of:

- (i) compounds having the formula (I):



wherein R represents -NH-CO-NH₂, -NH-CO-CH₃, or -OH group, and

- (ii) glucuronide derivatives thereof having the formula (II):



Attorney's Docket No. 033532-001

Application Serial No. 10/051,243

Page 4

A²
concl'd

wherein R is as above indicated, and

(iii) addition salts thereof.
